Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYBB | P04839 | 2/20 | 0.42 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311194 | 0.91 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL16003394 | 0.85 | ALDH1A1 (0.49) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL30378305 | 0.85 | ALDH1A1 (0.49) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL3315110 | 0.85 | ALDH1A1 (0.49) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL30682408 | 0.84 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL31049787 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL18690528 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL16003519 | 0.82 | CYBB (0.42) | ALDH1A1CYBBNOX4NTSR1MTNR1A | |
| SCHEMBL3312302 | 0.82 | ALDH1A1 (0.40) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL17414788 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961750-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134308-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134308-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2435435-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102459264-A | Pyrimidine inhibitors of kinase activity | ABBOTT LAB | 2012-05-16 | — | — | CN | disclosed |
| CN-102459265-A | Pyrimidine inhibitors of kinase activity | ABBOTT LAB | 2012-05-16 | — | — | CN | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | ALDH1A1 1481/4885CYP3A4 3650/4885TDP1 309/4885 |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | ALDH1A1 982/4885CYP3A4 3939/4885TDP1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.